Fluconazole non-susceptible breakthrough candidemia after prolonged low-dose prophylaxis: a prospective FUNGINOS study.

Orasch, Christina; Mertz, Dominik; Garbino, Jorge; van Delden, Christian; Emonet, Stephane; Schrenzel, Jacques; Zimmerli, Stefan; Damonti, Lauro; Mühlethaler, Konrad; Imhof, Alexander; Ruef, Christian; Fehr, Jan; Zbinden, Reinhard; Boggian, Katia; Bruderer, Thomas; Flückiger, Ursula; Conen, Anna; Khanna, Nina; Frei, Reno; Bregenzer, Thomas; ... (2018). Fluconazole non-susceptible breakthrough candidemia after prolonged low-dose prophylaxis: a prospective FUNGINOS study. Journal of infection, 76(5), pp. 489-495. Elsevier 10.1016/j.jinf.2017.12.018

[img]
Preview
Text
Unbenannt.pdf - Accepted Version
Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND).

Download (849kB) | Preview
[img] Text
1-s2.0-S016344531830029X-main.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (442kB) | Request a copy

OBJECTIVES

Breakthrough candidemia (BTC) on fluconazole was associated with non-susceptible Candida spp. and increased mortality. This nationwide FUNGINOS study analyzed clinical and mycological BTC characteristics.

METHODS

3-year prospective study in 567 consecutive candidemias. Species identification and susceptibility testing (CLSI) in reference laboratory. Data analysis according to STROBE criteria.

RESULTS

43/576 (8%) BTC were studied: 37/43 (86%) on fluconazole (28 prophylaxis, median 200mg/day). 21% BTC vs. 23% non-BTC presented severe sepsis/septic shock. Overall mortality was 34% vs. 32%. BTC was associated with gastrointestinal mucositis (multivariate OR 5.25, 95%CI 2.23-12.40, p<0.001) and graft-versus-host-disease (6.25, 1.00-38.87, p=0.05), immunosuppression (2.42, 1.03-5.68, p=0.043), parenteral nutrition (2.87, 1.44-5.71, p=0.003). Non-albicans Candida were isolated in 58% BTC vs. 35% non-BTC (p=0.005). 63% of 16 BTC occurring after 10-day fluconazole were non-susceptible (Candida glabrata, Candida krusei, Candida norvegensis) vs. 19% of 21 BTC (C. glabrata) following shorter exposure (7.10, 1.60-31.30, p=0.007). Median fluconazole MIC was 4mg/l vs. 0.25mg/l (p<0.001). Ten-day fluconazole exposure predicted non-susceptible BTC with 73% accuracy.

CONCLUSIONS

Outcome of BTC and non-BTC was similar. Fluconazole non-susceptible BTC occurred in three out of four cases after prolonged low-dose prophylaxis. This implies reassessment of prophylaxis duration and rapid de-escalation of empirical therapy in BTC after short fluconazole exposure.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Service Sector > Institute for Infectious Diseases
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Infectiology
04 Faculty of Medicine > Service Sector > Institute for Infectious Diseases > Parasitology

UniBE Contributor:

Zimmerli, Stefan; Damonti, Lauro and Mühlethaler, Konrad

Subjects:

500 Science > 570 Life sciences; biology
600 Technology > 610 Medicine & health

ISSN:

0163-4453

Publisher:

Elsevier

Language:

English

Submitter:

Annelies Luginbühl

Date Deposited:

25 Apr 2018 09:27

Last Modified:

18 May 2020 11:11

Publisher DOI:

10.1016/j.jinf.2017.12.018

PubMed ID:

29378240

Uncontrolled Keywords:

Candida FUNGINOS. breakthrough candidemia fluconazole species susceptibility

BORIS DOI:

10.7892/boris.110723

URI:

https://boris.unibe.ch/id/eprint/110723

Actions (login required)

Edit item Edit item
Provide Feedback